Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Exclusion Criteria

• •Participants with stage IV breast cancer
• •Participants currently taking statins
• •Uncontrolled hypertension (systolic blood pressure \>190 mm Hg or diastolic blood pressure \>100 mm Hg)
• •No active liver disease
• •Current use of CYP 3A4 inhibitors
• •Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study
• •Life expectancy \< 12 weeks
• •Pregnancy (positive pregnancy test) or lactation
• •Pre-existing sensory neuropathy \> grade one
• •Has significant cardiovascular disease, such as:
• •LVEF \< 50% at baseline as assessed by ECHO (preferred) i) Class III or Class IV myocardial disease as described by the New York Heart Association ii) Recent history (within 6 months prior to enrollment) of myocardial infarction; or iii) Symptomatic arrhythmia at the time of randomization
• •Major surgery without complete recovery in the past four weeks prior to screening
• •Concurrent active infection
• •Participant with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C
• •Participant who has a history of allergy or hypersensitivity to any of the study drugs
• •Participant with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis
• •Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study